Item 7.01. Regulation FD Disclosure.
On January 30, 2020, Corcept Therapeutics Incorporated (the "Company") issued a
press release announcing its preliminary fourth quarter and selected financial
results for the period ended December 31, 2019 . The press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02 and Item 7.01 and the information contained in
the press release attached as Exhibit 99.1 shall not be deemed filed for
purposes of Section 18 of the Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the
Securities Act of 1933, as amended. The information in this Item 2.02 and Item
7.01 and the information contained in the press release attached as Exhibit 99.1
is not incorporated by reference into any filing with the U.S. Securities and
Exchange Commission made by the Company, whether made before or after the date
hereof, regardless of any general incorporation language in the filing unless
specifically stated so therein.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibits No.   Description
        99.1     Press Release of Corcept Therapeutics Incorporated, dated January
               30, 2020.
       104.1   Cover Page Interactive Data File - the cover page XBRL tags are
               embedded within the Inline XBRL document.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses